Welcome to our dedicated page for Radnostix SEC filings (Ticker: INIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Radnostix, Inc. filings document the public-company record of the radioisotope manufacturer formerly known as International Isotopes Inc. Recent 8-K and information-statement disclosures record the amendment to its Texas formation documents changing the corporate name, shareholder written-consent approval, and the continued OTCQB trading of its common stock under INIS.
Other filings and event reports cover executive-compensation arrangements, material agreements, shareholder voting matters, capital-structure disclosure, operating and financial results, and regulatory matters connected with radioisotope, theranostics, medical-device, calibration and reference products.
Radnostix, Inc. entered an Asset Purchase Agreement to buy the Lara System technology platform and Ellexa Explorer software from Lucerno Dynamics. The initial purchase price is $900,000, split between $150,000 in cash and $750,000 in common stock valued using a 20‑day VWAP. The seller may receive up to an additional $750,000 in stock through regulatory and sales milestone payments, plus cash earn outs tied to future system sales.
The company also issued a $500,000 related party Convertible Promissory Note to Kershner Grosso & Co. maturing in 2031, bearing 5% annual interest and convertible into common stock at $0.07 per share, with a company call feature if the stock trades above $0.12 VWAP for 30 days. Radnostix amended several historic notes to remove liens on company assets, add similar conversion and forced‑conversion terms, and extend their maturities to March 31, 2031.
RADNOSTIX INC director and 10% owner Christopher G. Grosso, through Kershner, Grosso & Co., purchased a $500,000 convertible promissory note from the company. The note bears simple interest at 5% per year, with interest payable annually and optional paid-in-kind interest for the first two years.
The lender may convert principal and accrued interest into common stock at $0.07 per share, initially corresponding to 7,142,857 shares based on principal alone, subject to anti-dilution adjustments. RADNOSTIX can force conversion if the volume weighted-average closing price exceeds $0.12 per share over thirty consecutive trading days, and the instrument carries an expiration date of June 30, 2031.
Radnostix Inc. is asking shareholders to vote at its 2026 annual meeting on July 16, 2026. Holders of 529,130,353 shares of common stock outstanding as of May 26, 2026 can vote.
Shareholders will elect five directors, including CEO Shahe Bagerdjian and Chairman Christopher Grosso, ratify Haynie & Company as independent auditor for the year ending December 31, 2026, and approve the new Radnostix 2026 Incentive Plan.
The plan would reserve 12,000,000 shares for equity awards over ten years, covering about 40 employees and three non‑employee directors, replacing the expired 2015 plan. Executive pay includes 2025 total compensation of $1,483,567 for the CEO and $172,701 for the CFO, with the CEO holding performance‑based RSUs tied to share‑price hurdles from $0.10 to $0.30.
Ownership is concentrated, with Kennerman Associates Inc. at 42.4% and John M. McCormack and related parties at 20.6%, while director Christopher Grosso holds 12.2%. The filing also details related‑party promissory notes with former leadership and confirms all required Section 16(a) reports were filed, aside from one late Form 4.
Radnostix Inc. has amended the terms of its Series C Convertible Redeemable Preferred Stock after approval by a majority of the Series C holders. The change extends the security’s maturity date by one year, moving it to February 28, 2028, while all other terms remain the same.
To implement this change, the company filed a Certificate of Amendment to the Statement of Designation for the Series C preferred stock with the Texas Secretary of State. The amendment formalizes the new maturity date without altering dividend, conversion, or other stated rights.
Radnostix Inc. reported weaker results for the quarter ended March 31, 2026. Sale of product fell to $2,378,924 from $3,238,900, a 27% drop, driven by lower Theranostics, Cobalt, and Calibration & Reference segment revenue.
Net loss widened sharply to $1,348,086 from $112,694 as gross margin compressed to 48% from 63% and operating expenses rose 17% to $2,460,980. Results were hurt by two voluntary recalls in Theranostics, a cobalt production shutdown for hot-cell rehabilitation, and continued isotope supply constraints.
Cash and cash equivalents were $1,347,394 and total cash, cash equivalents, and restricted cash were $2,852,931. Management expects existing cash, operations, and potential financing to fund the next 12 months but notes dependence on key customers, suppliers, and ongoing access to capital.
Radnostix Inc. filed a Notification of Late Filing (Form 12b-25) stating it could not timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 because additional time is needed to complete valuation and accounting analyses of certain stock-based compensation awards, including restricted stock units. The company expects to file the Form 10-Q within the five-day extension period.
The filing discloses operating results for the three months ended March 31, 2026: Sales $2,378,924 versus $3,238,900 for the same period in 2025 (a decrease of approximately 27%). Radnostix expects a net loss of $1,100,000 to $1,300,000 for the quarter, versus a net loss of $112,694 in the prior-year period, attributing the change mainly to decreased sales after voluntary recalls and an operational shutdown for rehabilitation.
Radnostix, Inc. disclosure: Kennerman Associates, Inc. reports beneficial ownership of 237,489,559 shares of common stock, representing 42.4% of the class based on March 26, 2026. The holding includes 5,000,000 vested options exercisable within 60 days and 26,300,000 shares issuable on conversion of Series C Preferred Stock.
Christopher Grosso is identified as a principal of Kennerman Associates and is reported as beneficially owning 65,645,540 shares (12.1%), which includes options and Series C conversion rights; Grosso disclaims beneficial ownership of a portion of the securities reported.
RADNOSTIX INC director and 10% owner Christopher G. Grosso reported non-market restructuring transactions involving 581,536 shares of Common Stock. These entries reflect shares issued in lieu of cash dividends on the company’s Series C Redeemable Convertible Preferred Stock, at the holder’s option, rather than open-market buying or selling.
The shares were allocated across several indirect accounts, including a credit shelter trust and UTMA custodial accounts for his children, as well as his direct holdings. After these stock-dividend issuances, his reported direct Common Stock position was 38,477,083 shares, with additional indirect holdings in the related accounts.
Radnostix Inc. files an amended annual report to add detailed disclosures on directors, executive compensation, share ownership, related‑party dealings and auditor fees for the year ended December 31, 2025.
The filing highlights a five‑member board with Nasdaq‑independent committees, a performance‑ and stock‑based package for the CEO, concentration of ownership among two large shareholders, insider promissory notes that can convert into equity, and audit fees of about $122,000 per year paid to Haynie & Company.
Radnostix Inc. reported 2025 revenue of $13.1 million, down about 6% from 2024, and swung to a net loss of $908,002 after a small profit in the prior year. Gross margin remained relatively strong at 59% but was slightly lower than 62% in 2024.
Theranostics Products stayed the largest segment at $6.8 million, though sales fell 15% due to radioisotope supply outages and softer demand from a major customer. Cobalt Products revenue declined 26% to $1.8 million, partly because the company shut cobalt production hot cells in late 2025 for refurbishment.
Calibration & Reference Products grew 21% to $4.25 million, helped by a full year of cobalt‑57 supply and new PET-focused products, offset by a gadolinium‑153 isotope outage. The Medical Devices segment remained small but rose sharply to $229,000 as initial distribution activity ramped up.
Operating expenses were flat at about $8.7 million, with higher salaries offset by lower legal, professional, and R&D spending. Radnostix generated $620,000 of operating cash flow and ended 2025 with $1.7 million in cash. The company also terminated a planned $12.45 million sale of its DUF6 de‑conversion assets, retaining those assets and related NRC licenses for future strategic options.